Revvity, Inc. (RVTY) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Analyst target reached at $101.52 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth.
Revvity provides health science solutions across Life Sciences (instruments, reagents, software for drug discovery) and Diagnostics (screening, immunodiagnostics, reproductive health) segments marketed in 160+ countries. As of December 28, 2025, it employed ~11,000 employees.... Read more
Sell if holding. Analyst target reached at $101.52 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 46d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-12Recent Developments — Revvity, Inc.
Latest news
- NEWS Is Revvity Inc (RVTY) a Bargain After 3.4% Drop? GF Value Says U - GuruFocus — GuruFocus neutral
- NEWS Revvity, Inc. announces Quarterly dividend, payable on August 07, 2026 - marketscreener.com — marketscreener.com neutral
- NEWS Revvity (NYSE:RVTY) Hits New 52-Week Low - Time to Sell? - MarketBeat — MarketBeat negative
- NEWS Universal Beteiligungs und Servicegesellschaft mbH Sells 42,142 Shares of Revvity Inc. $RVTY - MarketBeat — MarketBeat negative
- NEWS Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch — MarketWatch negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $101.52 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $94.41. Score 5.1/10, moderate confidence.
Take-profit target: $104.08 (+2.5% upside). Prior stop was $94.41. Stop-loss: $94.41.
Analyst target reached - limited upside remaining; Weak growth.
Revvity, Inc. trades at a P/E of 48.7 (forward 17.4). TrendMatrix value score: 5.8/10. Verdict: Sell.
24 analysts cover RVTY with a consensus score of 3.8/5. Average price target: $114.
What does Revvity, Inc. do?Revvity provides health science solutions across Life Sciences (instruments, reagents, software for drug discovery) and...
Revvity provides health science solutions across Life Sciences (instruments, reagents, software for drug discovery) and Diagnostics (screening, immunodiagnostics, reproductive health) segments marketed in 160+ countries. As of December 28, 2025, it employed ~11,000 employees. Revenue comes from instruments, reagents, software, and related services sold to pharma, biotech, clinical labs, and research institutions.